Best biotech stocks 2026, scored against 7 investor frameworks
Ten biotech names ranked by how they hold up against Buffett, Graham, Fisher, Lynch, Greenblatt, Munger, and Smith. Pipeline reads, balance-sheet reads, and a link to the full per-ticker verdict.
Last reviewed: · Educational only. Not investment advice.
Biotech is the hardest sector to apply value investing to. Earnings volatility is structural, R&D outcomes are binary, and the difference between a USD 200 billion franchise and a zero is one phase-3 readout. The result is that most pre-revenue biotechs sit outside any disciplined value framework. Only a minority of biotechs (the ones with established commercial franchises, real free cash flow, and balance sheets that can survive a missed pipeline shot) pass the seven-framework lens. Those are the names worth a closer look in 2026, especially as the obesity-drug wave creates rotation pressure across the entire healthcare complex.
The list below applies the same seven investor frameworks that invest-like uses on every ticker. Stocks that pass several frameworks at once are flagged. Stocks that pass only one or two are tagged with the specific reason the others fail. The reads below come from the same documented methodology that powers the per-ticker pages on the platform.
01
REGNRegeneron Pharmaceuticals
An R&D-led biotech with Eylea franchise in ophthalmology and Dupixent royalty stream from Sanofi.
Fisher and Smith pass strongly: highest R&D productivity in the cohort and a long runway on Dupixent. Buffett is comfortable with the moat in Eylea, less comfortable with the biosimilar overhang. Greenblatt picks it up on the EV/EBIT compression. Graham is mixed (clean balance sheet, but earnings stability is shakier with Eylea generics looming).
Frameworks that pass
Fisher
Smith
Greenblatt
Frameworks that fail
Graham (Eylea biosimilar risk)
Key risk to know
Eylea biosimilar erosion and pricing pressure from interchangeable competition. The Dupixent royalty cushions the cliff but does not eliminate it.
Effective monopoly in cystic fibrosis, with a growing pain franchise (Journavx) and gene therapy in sickle cell (Casgevy).
Buffett, Munger, and Smith all pass it: the cystic fibrosis franchise is one of the cleanest moats in pharma, with no on-market competition. Fisher likes the R&D pipeline. Lynch struggles on PEG at the current multiple. Graham fails on cheapness. Greenblatt is borderline.
Frameworks that pass
Buffett
Munger
Smith
Fisher
Frameworks that fail
Graham
Lynch (PEG)
Key risk to know
Pipeline diversification. Vertex needs Casgevy, Journavx, and the kidney program to scale before any cystic fibrosis erosion. The thesis depends on franchise diversification working.
HIV franchise leader with Biktarvy, plus Trodelvy in oncology and an established hepatitis C franchise.
Graham passes it on cheapness, balance sheet, and dividend sustainability. Greenblatt picks it up on Magic Formula. Munger and Buffett are mixed on the moat, since the HIV franchise faces eventual Biktarvy patent erosion. Lynch is fine with the story at the current multiple. Smith is neutral on the oncology pivot.
Frameworks that pass
Graham
Greenblatt
Lynch
Frameworks that fail
Smith (oncology execution)
Key risk to know
Lenacapavir launch and Biktarvy patent cliff convergence. Both events crystallize in the 2027 to 2030 window.
Large-cap biotech with established franchises (Enbrel, Prolia, Repatha) and a key obesity drug candidate in MariTide.
Graham and Greenblatt both pass it: cheap on most measures, dividend stable, balance sheet manageable post Horizon. Smith fails on the leverage and capital intensity. Lynch likes the MariTide optionality. Buffett is mixed on the moat (declining Enbrel, untested MariTide).
Frameworks that pass
Graham
Greenblatt
Lynch
Frameworks that fail
Smith (leverage)
Buffett (moat erosion)
Key risk to know
MariTide clinical and commercial execution. The obesity-drug TAM is enormous, but Amgen is entering against entrenched Novo and Lilly competition.
Neurology-focused biotech with Spinraza, Leqembi (Alzheimer's), and a multiple sclerosis franchise in decline.
Graham can pass on extreme cheapness. The other frameworks largely fail it. Buffett, Munger, and Smith all see eroding moats. Lynch struggles with the story (Leqembi adoption has been slower than the bull case). Greenblatt picks it up episodically when EV/EBIT compresses, but the ROIC trend is unfavorable.
Frameworks that pass
Graham
Frameworks that fail
Buffett
Smith
Lynch
Munger
Key risk to know
Leqembi adoption pace. The Alzheimer's launch is the thesis, and infusion-site capacity, payer coverage, and patient screening are the bottleneck.
Leader in RNAi therapeutics, with Amvuttra in ATTR amyloidosis and a broad pipeline across rare disease and cardiovascular.
Fisher passes strongly on platform R&D quality. Munger is positive on the long-term thesis. Buffett is cautious until the cash-flow profile inflects. Graham fails on profitability and balance sheet. Lynch is mixed (high growth, but PEG is hard to assess pre-inflection). Greenblatt fails on current ROIC.
Frameworks that pass
Fisher
Munger (qualitative)
Frameworks that fail
Graham
Greenblatt
Smith
Key risk to know
Amvuttra commercial ramp and pipeline conversion. The transition from R&D-stage to durably profitable is the entire near-term thesis.
mRNA platform company, with COVID franchise post-peak, RSV vaccine on market, and an early oncology and rare-disease pipeline.
Graham passes on cash on the balance sheet, but earnings have collapsed off COVID highs and stability is poor. Fisher is positive on the platform but skeptical of monetization speed. Lynch fails on story (post-COVID story is unproven). Buffett and Smith both fail it on capital intensity and uncertain moat.
Frameworks that pass
Graham (cash)
Fisher (platform)
Frameworks that fail
Buffett
Smith
Lynch
Greenblatt
Key risk to know
Cash burn vs. pipeline timing. Moderna is spending aggressively on the mRNA platform, and the next blockbuster has to land before the COVID cash runway is depleted.
Rare disease specialist with Voxzogo in achondroplasia and a portfolio of enzyme replacement therapies.
Lynch and Fisher both pass on growth-quality and pipeline breadth. Graham is mixed on profitability. Greenblatt picks it up when the multiple compresses. Buffett and Munger are cautious on the gene therapy capital allocation history. Smith is neutral.
Frameworks that pass
Lynch
Fisher
Frameworks that fail
Buffett (capital allocation)
Key risk to know
Voxzogo expansion in younger children and Roctavian commercial realization. The two products carry most of the next three years of growth.
Dominant sequencing-instruments and consumables franchise, recovering from the GRAIL divestiture.
Buffett and Munger see the moat clearly (razor-and-blade economics in sequencing consumables) and pass it. Smith likes the ROCE if the GRAIL distraction stays cleaned up. Fisher passes on R&D. Graham fails on multiple. Lynch is fine with the story. Greenblatt is borderline.
Frameworks that pass
Buffett
Munger
Smith
Fisher
Frameworks that fail
Graham (multiple)
Key risk to know
Sequencing pricing pressure from MGI/CG, plus the still-developing post-GRAIL strategic narrative.
Mid-cap biotech with Cabometyx in renal and liver cell carcinoma, growing into earlier-line indications.
Graham passes on cash and balance sheet. Greenblatt picks it up on ROIC. Lynch likes the PEG. Buffett is cautious on the single-asset concentration. Smith fails on durability. Fisher is mixed.
Frameworks that pass
Graham
Greenblatt
Lynch
Frameworks that fail
Smith (single-asset risk)
Key risk to know
Cabometyx patent timeline and the pace of pipeline replacement. Single-asset biotech profiles have notoriously violent transitions when patent cliffs arrive.
The ten names above were drawn from the largest US-listed biotechs by market capitalization, filtered for at least one approved commercial product, and weighted toward names with the deepest coverage on invest-like. Pre-revenue platform biotechs were excluded since they fail cross-framework consensus by design (no cash flows yet to discipline the analysis). The seven frameworks are documented in full at the methodology page.
The all-pass consensus signal is benchmarked over five years against the S&P 500 at the benchmarks page. Biotech consensus signals tend to be rarer than in other sectors, because earnings volatility and binary R&D outcomes stress the Graham and Smith pillars. That rarity is the point. Educational only, never investment advice.
Frequently asked questions
How were these 10 biotech stocks selected?
We started from the largest US-listed biotech names by market capitalization, prioritized companies with at least one approved commercial product, and weighted toward names with the deepest coverage on invest-like. The selection is opinionated, not statistical.
Why are no pure-play oncology platforms on the list?
Pre-revenue platform biotechs almost universally fail the seven-framework consensus, because Graham, Greenblatt, Smith, and Buffett all require demonstrated cash generation. Platform names like CRSP and BEAM are tracked individually on invest-like but rarely pass cross-framework agreement until they have an approved commercial asset.
What are the seven investor frameworks?
Buffett (moat plus capital allocation plus durability), Graham (cheapness plus balance-sheet safety plus earnings stability), Fisher (growth quality plus R&D efficiency plus management), Lynch (PEG plus story plus growth-at-reasonable-price), Greenblatt (Magic Formula, ROIC plus EV/EBIT), Munger (high quality plus willingness to pay up), and Smith (ROCE plus organic growth plus low capital intensity).
Is biotech a value-investing-friendly sector?
Selectively. The handful of biotechs with established franchises, real R&D productivity, and clean balance sheets (VRTX, REGN, GILD) have compounded effectively. The much larger pre-revenue platform biotech universe is generally outside the value-investing lens, since it requires forward-looking pipeline judgement rather than historical financials.
Are these buy recommendations?
No. This is educational analysis only. invest-like grades stocks against documented frameworks so investors can make their own informed decisions. Nothing on this page is investment advice, an offer, or a solicitation. Past performance does not guarantee future results.
How often is this list updated?
Underlying per-ticker scoring updates daily on invest-like. This listicle is reviewed quarterly with the next review scheduled August 2026.
Where can I see the full Buffett verdict on each name?
Each entry links to /buffett/[ticker]/ where the full five-pillar verdict (moat, durability, management, financial health, valuation) is written out with reasoning.
Educational only. Nothing on this page constitutes investment advice, an offer, or a solicitation to buy or sell any security. Framework reads represent the opinion of invest-like. Verify financials independently. Past performance does not guarantee future results.
Best biotech stocks 2026, scored against 7 investor frameworks · invest-like